3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Leukemia, Myeloid, Acute
25
Breast Neoplasms
14
Neoplasms
12
Myelodysplastic Syndromes
12
Prostatic Neoplasms
10
Multiple Myeloma
8
Lung Neoplasms
7
Stomach Neoplasms
6
Sarcoma
6
Ovarian Neoplasms
5
Leukemia, Myelomonocytic, Chronic
5
Recurrence
4
Neoplasm Metastasis
4
Lymphoma, Non-Hodgkin
4
Head and Neck Neoplasms
4
Colorectal Neoplasms
4
Carcinoma, Non-Small-Cell Lung
4
Advanced Solid Tumor
4
Uterine Cervical Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
3
Solid Tumor
3
Small Cell Lung Carcinoma
3
Pain
3
Mucositis
3
Lymphoma, T-Cell, Peripheral
3
Cholangiocarcinoma
3
Carcinoma, Transitional Cell
3
Carcinoma, Hepatocellular
3
Stomatitis
2
Skin Neoplasms
2
Interventions
etrolizumab
5
Infliximab
4
Adalimumab
3
golimumab
2
CT-P13
2
peficitinib
1
Sutures
1
Surgical Instruments
1
Ringer's Lactate
1
Proctectomy
1
Pneumococcal Vaccines
1
Papillomavirus Vaccines
1
Methylprednisolone
1
Mesalamine
1
Lysine Acetyltransferase 5
1
Laparoscopy
1
Injections
1
Hydroxyethyl Starch Derivatives
1
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
1
Eicosapentaenoic Acid
1
CVD protocol
1
ABX464
1
2-(3',4'-dihydroxyphenyl-1-azo)benzimidazole
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Colitis, Ulcerative
×
Injections
×
Clear all
NCT02136069
2021-12-03
GARDENIA
Hoffmann-La Roche
Phase 3
Completed
397 enrolled
32 charts